Zobrazeno 1 - 10
of 1 414
pro vyhledávání: ''
Autor:
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Publikováno v:
Cancer Science. 113:4300-4310
Previous clinical trials indicate that 10%-25% of patients received genomically matched therapy after comprehensive genomic profiling (CGP) tests. However, the clinical utility of CGP tests has not been assessed in clinical practice. We assessed the
Autor:
Nobuyuki Yamamoto, Tetsu Kamitani, Kingo Kanda, Yuichiro Ito, Masahiro Hamada, Masahiko Ozaki, Noriko Takeuchi, Tomoko Yamada, Masaki Kawano, Shinichiroh Maekawa, Terufumi Kato
Publikováno v:
Cancer Science. 113:3110-3119
This post-marketing surveillance (PMS) was initiated in Japan to identify factors affecting the safety and effectiveness of pembrolizumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with programmed cell death ligand-1 (PD
Autor:
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Publikováno v:
Cancer Science. 113:2109-2117
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor proportion scor
Autor:
Tetsu Hayashida, Aiko Nagayama, Tomoko Seki, Maiko Takahashi, Akiko Matsumoto, Anna Kubota, Hiromitsu Jinno, Hiroaki Miyata, Yuko Kitagawa
Publikováno v:
Cancer Science. 113:1722-1730
Due to the increasing complexity of cancer treatment, ensuring safety and maintaining the quality of life during treatment are important issues. Patient-reported outcomes (PROs) in oncology are essential for assessing patient symptoms. A feasibility
Autor:
Masatoshi Kanayama, Taiji Kuwata, Masataka Mori, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Hiroki Matsumiya, Akihiro Taira, Shinji Shinohara, Masaru Takenaka, Kazue Yoneda, Koji Kuroda, Takashi Ohnaga, Fumihiro Tanaka
Publikováno v:
Cancer Science. 113:1028-1037
Detecting rare circulating tumor cells (CTCs) in the bloodstream is extremely challenging. We had previously developed a novel polymeric microfluidic device, "CTC-chip," for capturing CTCs and have shown high capture efficiency in lung cancer cell li
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Xianxian Wu, Hongdian Zhang, Zhilin Sui, Yongyin Gao, Lei Gong, Chuangui Chen, Zhao Ma, Peng Tang, Zhentao Yu
Publikováno v:
Cancer Science. 113:926-939
C-X-C motif chemokine receptor 4 (CXCR4) belongs to the CXC chemokine receptor family, which mediates the metastasis of tumor cells and promotes the malignant development of cancers. However, its biological role and regulatory mechanism in esophageal
Autor:
Sumiyo Okawa, Takahiro Tabuchi, Kayo Nakata, Toshitaka Morishima, Shihoko Koyama, Satomi Odani, Isao Miyashiro
Publikováno v:
Cancer Science. 113:1047-1056
In Japan, cancer care hospitals designated by the national government have a surgical volume requirement of 400 annually, which is not necessarily defined based on patient outcomes. This study aimed to estimate surgical volume thresholds that ensure
Autor:
Junko Kunieda, Kyoko Yamashita, Yuki Togashi, Satoko Baba, Seiji Sakata, Kentaro Inamura, Keisuke Ae, Seiichi Matsumoto, Rikuo Machinami, Masanobu Kitagawa, Kengo Takeuchi
Publikováno v:
Cancer Science. 113:1078-1089
Myxoid liposarcoma (MLPS) is genetically characterized by FUS-DDIT3 or EWSR1-DDIT3 gene fusion and the high frequency of hotspot mutations (C228T or C250T) in the promoter region of telomerase reverse transcriptase (TERT) that encodes the TERT protei
Autor:
Kotoe Oshima, Ken Kato, Yoshinori Ito, Hiroyuki Daiko, Isao Nozaki, Satoru Nakagawa, Yuichi Shibuya, Takashi Kojima, Yasushi Toh, Morihito Okada, Shuichi Hironaka, Yuji Akiyama, Yoshito Komatsu, Kazuhiro Maejima, Hidewaki Nakagawa, Ritsuko Onuki, Momoko Nagai, Mamoru Kato, Keisuke Kanato, Aya Kuchiba, Kenichi Nakamura, Yuko Kitagawa
Publikováno v:
Cancer Science. 113:1018-1027
We undertook genomic analyses of Japanese patients with stage I esophageal squamous cell carcinoma (ESCC) to investigate the frequency of genomic alterations and the association with survival outcomes. Biomarker analysis was carried out for patients